Enlivex Ltd. ENLV
Annual
Quarterly
No annual revenue total was found in Enlivex Ltd.'s SEC filings.
Enlivex Ltd. (ENLV) files with the SEC under industry code 6199, Finance Services. Free cash flow was -$10.5 million. As of Dec 31, 2025 it held $1.9 million in cash and investments and $641,000 in total debt.
Revenue
—
Net income
$1.24B
+8329.2% vs prior year
Operating cash flow
$-10.42M
+19.9% vs prior year
Free cash flow
$-10.48M
+20.0% vs prior year
EPS
$25.48
+3590.4% vs prior year
Dividend per share
None
Shares outstanding
237.38M
+903.7% vs prior year
Net cash
$1.25M
FY 2025
Operating margin
—
Company profile
- Industry
- Finance Services (SIC 6199)
- Listed as
- ENLV (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- Israel
- Headquarters
- Tel Aviv
- SEC filer status
- Non-accelerated filer
- SEC CIK
- 1596812
- Former names
- Enlivex Therapeutics Ltd. (until Feb 10, 2026); Bioblast Pharma Ltd. (until Mar 18, 2019); BIO BLAST PHARMA LTD. (until Sep 12, 2016)
Other Finance Services companies
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Operating income | -$15.0M | -$15.9M | -$29.4M | -$25.8M | -$19.3M |
| Net income | $1.2B | -$15.0M | -$29.1M | -$31.1M | -$14.5M |
| Diluted EPS | $25.48 | -$0.73 | -$1.56 | -$1.69 | — |
| Operating cash flow | -$10.4M | -$13.0M | -$23.5M | -$24.0M | -$17.5M |
| Free cash flow | -$10.5M | -$13.1M | -$23.8M | -$32.1M | -$19.2M |
| Total assets | $2.3B | $27.7M | $36.8M | $67.6M | $95.1M |
| Total liabilities | $392.1M | $4.1M | $6.7M | $10.8M | $10.1M |
| Stockholders' equity | $1.9B | $23.6M | $30.1M | $56.8M | $85.0M |
| Cash and investments | $1.9M | $3.5M | $5.9M | $49.9M | $74.1M |
| Total debt | $641,000 | $534,000 | $1.0M | — | — |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 6-K | Current report (foreign issuer) | Nov 2, 2026 | Nov 2, 2026 |
| 6-K | Current report (foreign issuer) | Oct 28, 2026 | Oct 28, 2026 |
| 6-K | Current report (foreign issuer) | Oct 27, 2026 | Oct 27, 2026 |
| 6-K | Current report (foreign issuer) | Oct 22, 2026 | Oct 22, 2026 |
| 6-K | Current report (foreign issuer) | Oct 19, 2026 | Oct 19, 2026 |
| 6-K/A | Amendment no. 2 to form 6-k | Oct 2, 2026 | Oct 2, 2026 |
All 419 Enlivex Ltd. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.